Greek
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
triterpene/φλεγμονή
Ο σύνδεσμος αποθηκεύεται στο πρόχειρο
Σελίδα 1 από 16 Αποτελέσματα
Triterpene derivatives for the treatment of cancer and inflammatory disease by inhibition of NF-.kappa.B
Μόνο εγγεγραμμένοι χρήστες μπορούν να μεταφράσουν άρθρα
Σύνδεση εγγραφή
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to the use of certain triterpenes which are inhibitors of nuclear factor kappa B (NF-.sub..kappa.B). In particular, it relates to useful triterpenes and pharmaceutical compositions containing them for use in the treatment
Triterpene saponins having anti-inflammatory, mucolytic and antiedemic activities, process for the preparation thereof and pharmaceutical compositions containing them
Μόνο εγγεγραμμένοι χρήστες μπορούν να μεταφράσουν άρθρα
Σύνδεση εγγραφή
The present invention relates to two novel triterpene saponins, having antiinflammatory, mucolytic and antiedemic activity, of general formula ##STR2## wherein: R.sub.1 is H or OH, and
R.sub.2 is a tetrasaccharide residue having 573 mass units or, alternatively, a pentasaccharide residue having 705
Combinations of diterpene triepoxide lactones and ditepene lactones or triterpenes for synergistic inhibition of cyclooxygenase-2
Μόνο εγγεγραμμένοι χρήστες μπορούν να μεταφράσουν άρθρα
Σύνδεση εγγραφή
FIELD OF THE INVENTION
The present invention relates generally to a composition exhibiting synergistic inhibition of the expression and/or activity of inducible cyclooxygenase-2 (COX-2). More particularly, the composition comprises, as a first component, a diterpene triepoxide lactone species and,
Compositions that treat or inhibit pathological conditions associated with inflammatory response
Μόνο εγγεγραμμένοι χρήστες μπορούν να μεταφράσουν άρθρα
Σύνδεση εγγραφή
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates generally to compositions that can be used to treat or inhibit pathological conditions associated with tissue-specific activation of inflammation and/or NF.kappa.B, to methods of modulating inflammation, including in
Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response
Μόνο εγγεγραμμένοι χρήστες μπορούν να μεταφράσουν άρθρα
Σύνδεση εγγραφή
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates generally to synergistic compositions that treat or inhibit pathological conditions associated with tissue-specific activation of inflammation and to methods of modulating inflammation in cells. More specifically,
Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response
Μόνο εγγεγραμμένοι χρήστες μπορούν να μεταφράσουν άρθρα
Σύνδεση εγγραφή
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates generally to synergistic compositions that treat or inhibit pathological conditions associated with tissue-specific activation of inflammation and to methods of modulating inflammation in cells. More specifically,
Compositions that treat or inhibit pathological conditions associated with inflammatory response
Μόνο εγγεγραμμένοι χρήστες μπορούν να μεταφράσουν άρθρα
Σύνδεση εγγραφή
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates generally to compositions that can be used to treat or inhibit pathological conditions associated with tissue-specific activation of inflammation and/or NF.kappa.B, to methods of modulating inflammation, including in
Compositions that treat or inhibit pathological conditions associated with inflammatory response
Μόνο εγγεγραμμένοι χρήστες μπορούν να μεταφράσουν άρθρα
Σύνδεση εγγραφή
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates generally to compositions that can be used to treat or inhibit pathological conditions associated with tissue-specific activation of inflammation and/or NF.kappa.B, to methods of modulating inflammation, including in
Compositions that treat or inhibit pathological conditions associated with inflammatory response
Μόνο εγγεγραμμένοι χρήστες μπορούν να μεταφράσουν άρθρα
Σύνδεση εγγραφή
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates generally to compositions that can be used to treat or inhibit pathological conditions associated with tissue-specific activation of inflammation and/or NF.kappa.B, to methods of modulating inflammation, including in
Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response
Μόνο εγγεγραμμένοι χρήστες μπορούν να μεταφράσουν άρθρα
Σύνδεση εγγραφή
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates generally to synergistic compositions that treat or inhibit pathological conditions associated with tissue-specific activation of inflammation and to methods of modulating inflammation in cells. More specifically,
Compositions that treat or inhibit pathological conditions associated with inflammatory response
Μόνο εγγεγραμμένοι χρήστες μπορούν να μεταφράσουν άρθρα
Σύνδεση εγγραφή
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates generally to compositions that can be used to treat or inhibit pathological conditions associated with tissue-specific activation of inflammation and/or NF.kappa.B, to methods of modulating inflammation, including in
Combination of pentacyclic triterpenes and hydroxytyrosol and derivatives thereof
Μόνο εγγεγραμμένοι χρήστες μπορούν να μεταφράσουν άρθρα
Σύνδεση εγγραφή
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is filed under the provisions of 35 U.S.C. .sctn. 371 and claims the priority of International Patent Application No. PCT/EP2014/062269 filed on 12 Jun 2014 entitled "COMBINATION OF PENTACYCLIC TRITERPENES AND HYDROXYTYROSOL AND DERIVATIVES
Triterpene derivatives
Μόνο εγγεγραμμένοι χρήστες μπορούν να μεταφράσουν άρθρα
Σύνδεση εγγραφή
BACKGROUND OF THE INVENTION
The present invention relates to new products of pharmacological interest and, more specifically, to new derivatives of glycyrrhetinic acid characterized by their pharmacological effect as inhibitors of gastroduodenal ulcers.
Glycyrrhetinic acid is prepared from
Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
Μόνο εγγεγραμμένοι χρήστες μπορούν να μεταφράσουν άρθρα
Σύνδεση εγγραφή
FIELD OF THE INVENTION
The present invention relates generally to a composition exhibiting synergistic inhibition of the expression and/or activity of inducible cyclooxygenase-2 (COX-2). More particularly, the composition comprises, as a first component, a curcuminoid species and, as a second
Avicin coated stents
Μόνο εγγεγραμμένοι χρήστες μπορούν να μεταφράσουν άρθρα
Σύνδεση εγγραφή
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates generally to at least the field of medicine. More specifically, it relates to compositions and methods regarding triterpene-coated stents.
2. Description of Related Art
One of the leading causes of death in the
Η πληρέστερη βάση δεδομένων φαρμακευτικών βοτάνων που υποστηρίζεται από την επιστήμη
- Λειτουργεί σε 55 γλώσσες
- Βοτανικές θεραπείες που υποστηρίζονται από την επιστήμη
- Αναγνώριση βοτάνων με εικόνα
- Διαδραστικός χάρτης GPS - ετικέτα βότανα στην τοποθεσία (σύντομα)
- Διαβάστε επιστημονικές δημοσιεύσεις που σχετίζονται με την αναζήτησή σας
- Αναζήτηση φαρμακευτικών βοτάνων με τα αποτελέσματά τους
- Οργανώστε τα ενδιαφέροντά σας και μείνετε ενημερωμένοι με την έρευνα ειδήσεων, τις κλινικές δοκιμές και τα διπλώματα ευρεσιτεχνίας
Πληκτρολογήστε ένα σύμπτωμα ή μια ασθένεια και διαβάστε για βότανα που μπορεί να βοηθήσουν, πληκτρολογήστε ένα βότανο και δείτε ασθένειες και συμπτώματα κατά των οποίων χρησιμοποιείται.
* Όλες οι πληροφορίες βασίζονται σε δημοσιευμένη επιστημονική έρευνα
